Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 199

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

CD226 opposes TIGIT to disrupt Tregs in melanoma

Open access
Fourcade, Julien, Sun, Zhaojun, Chauvin, Joe-Marc, Ka, Mignane, Davar, Diwakar, Pagliano, Ornella, Wang, Hong, Saada, Sofiane, Menna, Carmine, Amin, Rada, Sander, Cindy, Kirkwood, John M., Korman, Alan J., Zarour, Hassane M. · 2018 · JCI Insight

Abstract

CD4+ Tregs impede T cell responses to tumors. They express multiple inhibitory receptors that support their suppressive functions, including T cell Ig and ITIM domain (TIGIT). In melanoma patients, we show that Tregs exhibit increased TIGIT expression and decreased expression of its competing costimulatory receptor CD226 as compared with CD4+ effector T cells, resulting in an increased TIGIT/CD226 ratio. Tregs failed to upregulate CD226 upon T cell activation. TIGIT+ Tregs are highly suppressive, stable, and enriched in tumors. TIGIT and CD226 oppose each other to augment or disrupt, respectively, Treg suppression and stability. A high TIGIT/CD226 ratio in Tregs correlates with increased Treg frequencies in tumors and poor clinical outcome upon immune checkpoint blockade. Altogether, our findings show that a high TIGIT/CD226 ratio in Tregs regulates their suppressive function and stability in melanoma. They provide the rationale for novel immunotherapies to activate CD226 in Tregs together with TIGIT blockade to counteract Treg suppression in cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.121157

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 199

Metadata

Authors
Fourcade, J., Sun, Z., Chauvin, J.-M., Ka, M., Davar, D., Pagliano, O., Wang, H., Saada, S., Menna, C., Amin, R., Sander, C., Kirkwood, J. M., Korman, A. J., & Zarour, H. M.
Venue
JCI Insight
Published
2018-07-25
Volume
3
Issue
14
ISSN
2379-3708 (ISSN-L)
OpenAlex
W2884495860
Cited by
199
References
6
FWCI
6.02
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD226 opposes TIGIT to disrupt Tregs in melanoma. https://app.cochat.ai/papers/10.1172/jci.insight.121157
The paper
Fourcade, J., Sun, Z., Chauvin, J.-M., Ka, M., Davar, D., Pagliano, O., Wang, H., Saada, S., Menna, C., Amin, R., Sander, C., Kirkwood, J. M., Korman, A. J., & Zarour, H. M. (2018). CD226 opposes TIGIT to disrupt Tregs in melanoma. JCI Insight. https://doi.org/10.1172/jci.insight.121157

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.